Table 4.
Organ system specific major congenital malformations in pregnancies of second-generation antipsychotic users. Comparisons to first-generation antipsychotic users
| Exposure | Cardiovascular | Central nervous system | Respiratory tract | Orofacial cleft | Gastrointestinal | Urogenital | Musculoskeletal | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prev 1/1000 | Adj. OR (95% CI) | Prev 1/1000 | Adj. OR (95% CI) | Prev 1/1000 | Adj. OR (95% CI) | Prev 1/1000 | Adj. OR (95% CI) | Prev 1/1000 | Adj. OR (95% CI) | Prev 1/1000 | Adj. OR (95% CI) | Prev 1/1000 | Adj. OR (95% CI) | |
| Any F-GA | 21.6 | Ref | 6.9 | Ref | 2.0 | Ref | 2.0 | Ref | 2.9 | Ref | 7.9 | Ref | 19.6 | Ref |
| Any S-GA | 22.0 | 0.80 (0.44–1.44) | 2.3 | 0.53 (0.12–2.29) | 0.3 | 0.15 (0.00–5.85) | 1.7 | 0.67 (0.09–4.78) | 2.0 | 0.70 (0.12–3.98) | 7.8 | 0.62 (0.24–1.60) | 12.4 | 0.67 (0.32–1.38) |
| Quetiapine | 21.6 | 0.74 (0.38–1.44) | 2.3 | 0.36 (0.07–1.76) | 0.0 | NA | 0.8 | 0.48 (0.03–6.92) | 0.8 | 0.20 (0.02–2.28) | 7.6 | 0.60 (0.21–1.66) | 10.3 | 0.59 (0.24–1.42) |
| Olanzapine | 31.5 | 0.95 (0.41–2.16) | 4.8 | 0.98 (0.15–6.49) | 2.4 | 1.91 (0.04–83.7) | 4.8 | 2.05 (0.17–24.7) | 4.8 | 2.41 (0.24–24.6) | 9.7 | 0.95 (0.23–3.89) | 19.4 | 1.30 (0.46–3.66) |
| Risperidone | 12.4 | 0.46 (0.13–1.66) | 4.1 | 1.09 (0.11–11.3) | 0.0 | NA | 4.1 | 0.55 (0.01–20.4) | 4.1 | 1.31 (0.10–16.6) | 8.3 | 0.58 (0.11–3.20) | 16.5 | 0.76 (0.23–2.48) |
| Aripiprazole | 50.0 | 1.33 (0.50–3.54) | 0.0 | NA | 0.0 | NA | 4.5 | 0.47 (0.01–29.0) | 4.5 | 3.03 (0.12–76.0) | 9.1 | 0.54 (0.08–3.58) | 13.6 | 0.57 (0.12–2.73) |
Analyses based on imputed data
S-GA second-generation antipsychotic, F-GA first-generation antipsychotic, Prev prevalence, Adj. OR adjusted odds ratio adjusted for year of delivery and covariates associated with exposure and outcome at P < 0.1